BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27108364)

  • 1. The quantified EEG characteristics of responders and non-responders to long-term treatment with atomoxetine in children with attention deficit hyperactivity disorders.
    Chiarenza GA; Chabot R; Isenhart R; Montaldi L; Chiarenza MP; Torto MG; Prichep LS
    Int J Psychophysiol; 2016 Jun; 104():44-52. PubMed ID: 27108364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurophysiologic predictors of response to atomoxetine in young adults with attention deficit hyperactivity disorder: a pilot project.
    Leuchter AF; McGough JJ; Korb AS; Hunter AM; Glaser PE; Deldar A; Durell TM; Cook IA
    J Psychiatr Res; 2014 Jul; 54():11-8. PubMed ID: 24726639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
    Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can EEG Predict Response to Atomoxetine in attention deficit hyperactivity disorder at 1 Week?
    Singh G; Arun P; Das S; Kaur D
    J Atten Disord; 2021 Mar; 25(5):758-767. PubMed ID: 30762472
    [No Abstract]   [Full Text] [Related]  

  • 5. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
    Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
    Tanaka Y; Rohde LA; Jin L; Feldman PD; Upadhyaya HP
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):262-70. PubMed ID: 23683141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
    Yang R; Gao W; Li R; Zhao Z
    Int J Neuropsychopharmacol; 2015 Apr; 18(8):. PubMed ID: 25896257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
    Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
    Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.
    Smith T; Aman MG; Arnold LE; Silverman LB; Lecavalier L; Hollway J; Tumuluru R; Hyman SL; Buchan-Page KA; Hellings J; Rice RR; Brown NV; Pan X; Handen BL
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):868-876.e2. PubMed ID: 27663942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative EEG in Children and Adults With Attention Deficit Hyperactivity Disorder: Comparison of Absolute and Relative Power Spectra and Theta/Beta Ratio.
    Markovska-Simoska S; Pop-Jordanova N
    Clin EEG Neurosci; 2017 Jan; 48(1):20-32. PubMed ID: 27170672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.
    Bushe C; Sobanski E; Coghill D; Berggren L; De Bruyckere K; Leppämäki S
    CNS Drugs; 2016 Apr; 30(4):317-34. PubMed ID: 27055440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Lin HY; Gau SS
    Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv094. PubMed ID: 26377368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute atomoxetine effects on the EEG of children with attention-deficit/hyperactivity disorder.
    Barry RJ; Clarke AR; Hajos M; McCarthy R; Selikowitz M; Bruggemann JM
    Neuropharmacology; 2009 Dec; 57(7-8):702-7. PubMed ID: 19698723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.